|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
208,280,000 |
Market
Cap: |
1.69(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.56 - $15.86 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,693,990 |
Total Buy Value |
$0 |
$0 |
$0 |
$12,897,789 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
27 |
Total Shares Sold |
563,218 |
1,051,867 |
2,125,572 |
2,966,874 |
Total Sell Value |
$5,599,717 |
$10,026,707 |
$20,798,814 |
$28,193,476 |
Total People Sold |
4 |
7 |
8 |
8 |
Total Sell Transactions |
23 |
47 |
95 |
148 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Secora Michael |
Chief Financial Officer |
|
2024-04-17 |
4 |
AS |
$7.58 |
$175,349 |
D/D |
(23,124) |
1,231,055 |
|
-1% |
|
Secora Michael |
Chief Financial Officer |
|
2024-04-17 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,254,179 |
|
- |
|
Secora Michael |
Chief Financial Officer |
|
2024-04-16 |
4 |
AS |
$7.67 |
$191,658 |
D/D |
(25,000) |
1,216,679 |
|
-3% |
|
Secora Michael |
Chief Financial Officer |
|
2024-04-16 |
4 |
OE |
$2.22 |
$83,250 |
D/D |
37,500 |
1,241,679 |
|
- |
|
Borgeson Blake |
Director |
|
2024-04-16 |
4 |
AS |
$7.66 |
$87,725 |
D/D |
(11,447) |
7,229,861 |
|
-3% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-04-04 |
4 |
AS |
$9.02 |
$225,500 |
I/I |
(25,000) |
0 |
|
-16% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-04-04 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
25,000 |
|
- |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-04-04 |
4 |
AS |
$9.02 |
$360,800 |
D/D |
(40,000) |
938,524 |
|
-16% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-04-03 |
4 |
AS |
$8.84 |
$221,000 |
I/I |
(25,000) |
0 |
|
-18% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
25,000 |
|
- |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-04-03 |
4 |
AS |
$8.84 |
$353,600 |
D/D |
(40,000) |
978,524 |
|
-18% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-04-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
1,018,524 |
|
- |
|
Borgeson Blake |
Director |
|
2024-04-02 |
4 |
AS |
$8.82 |
$100,942 |
D/D |
(11,447) |
7,241,308 |
|
-16% |
|
Burrell Terry-Ann |
Director |
|
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,467 |
56,314 |
|
- |
|
Dar Zavain |
Director |
|
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,467 |
89,056 |
|
- |
|
Chavez R Martin Phd |
Director |
|
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,001 |
60,078 |
|
- |
|
Li Dean Y |
Director |
|
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,267 |
59,089 |
|
- |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-03-28 |
4 |
AS |
$10.10 |
$252,500 |
I/I |
(25,000) |
0 |
|
-26% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-03-28 |
4 |
A |
$0.00 |
$0 |
I/I |
25,000 |
25,000 |
|
- |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-03-28 |
4 |
AS |
$10.10 |
$404,000 |
D/D |
(40,000) |
1,043,524 |
|
-26% |
|
Gibson Christopher |
Chief Executive Officer |
|
2024-03-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
1,083,524 |
|
- |
|
Larson Tina Marriott |
President and COO |
|
2024-03-21 |
4 |
AS |
$10.70 |
$85,980 |
D/D |
(8,000) |
639,982 |
|
-31% |
|
Larson Tina Marriott |
President and COO |
|
2024-03-21 |
4 |
OE |
$1.06 |
$8,480 |
D/D |
8,000 |
647,982 |
|
- |
|
Borgeson Blake |
Director |
|
2024-03-19 |
4 |
AS |
$10.79 |
$216,423 |
D/D |
(20,054) |
7,252,755 |
|
-32% |
|
Secora Michael |
Chief Financial Officer |
|
2024-03-13 |
4 |
AS |
$11.03 |
$275,815 |
D/D |
(25,000) |
1,204,179 |
|
-33% |
|
616 Records found
|
|
Page 1 of 25 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|